{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "go:GO:0001525",
      "entity_text" : "neovascularization",
      "entity_type" : "bioprocess"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:P15692",
      "entity_text" : "Vegfa",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "XREF_BIBR, XREF_BIBR, XREF_BIBR, XREF_BIBR With current technology, the carrying capacity of delivery modules can be limited, so some of the most appealing opportunities for CRISPR-Cas therapies in ophthalmology lie in the targeting of autosomal dominant pathogenic alleles as well as the knockdown of specific wild-type genes that produce pathogenic phenotypes in specific locations, such as Vegfa in causing neovascularization of the choroid.",
  "reading_complete" : "2020-08-08T20:08:42Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T20:06:48Z",
  "trigger" : "causing",
  "evidence" : [ "Vegfa in causing neovascularization" ],
  "pmc_id" : "5450921",
  "score" : 0
}